Finland· FI-REL-REL18848
Telzir
A fosamprenavir product containing fosamprenavir calcium, registered in Finland by ViiV Healthcare BV. The same ATC class is registered in 8 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Fosamprenavir is registered in 8 of 19 countries.
Countries holding a registration under ATC J05AE07 (fosamprenavir), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Fosamprenavir · ATC J05AE07
8 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Franceprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of fosamprenavir costs, country by country.
Normalised to the WHO defined daily dose (1.4 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Fosamprenavir · price per daily dose (1.4 g)
USD · FX 28 Sept 2026
- FR France$13.86
The record
At a glance
Fimea (Finland)- Active substance
- Fosamprenavir calcium
- Manufacturer
- ViiV Healthcare BV
- Country
- Finland (FI)
- ATC code
- J05AE07
- ATC class
- Fosamprenavir
- Defined daily dose
- 1.4 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
336 interactions on record for fosamprenavir.
Graded by severity as the source publishes them — 116 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fosamprenavir · interactions on record
336 records
- 116 severe
- 186 moderate
- 7 minor
- 25 info
Most severe, free to view
- CisaprideA03FA02severe
- NaloxegolA06AH03severe
- LoperamideA07DA03severe
- BudesonideA07EA06severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fosamprenavir in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTelzir 50 mg/mlViiV Healthcare
- SpainTELZIR 50 MG/ML SUSPENSION ORALViiv Healthcare B.V.
- FranceTELZIR 50 mg/ml, suspension buvableVIIV HEALTHCARE UK (ROYAUME-UNI)
- PolandTelzirViiV Healthcare BV
- United StatesFosamprenavir CalciumSun Pharmaceutical Industries, Inc.
- United KingdomTelzir 50mg/ml oral suspensionViiV Healthcare UK Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc189314-7f19-4d2c-9dc7-c6262acfb6c3 GET /v1/drugs/dc189314-7f19-4d2c-9dc7-c6262acfb6c3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "1.4",
"form": "oraalisuspensio",
"route": "Suun kautta",
"ddd_unit": "g",
"strength": "50 mg/ml",
"atc_label": "fosamprenaviiri",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/04/282/002",
"fimea_rel_id": "REL18848",
"authorised_at": "2004-07-12"
}See everything about fosamprenavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.